BHST — BioHarvest Sciences Inc. Common Stock

Summary of BioHarvest Sciences Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• Revenue: Increased 8% year-over-year to $8.5 million, up from $7.9 million.
• Gross Profit: $5 million, representing 59% of total revenue, compared to $4.6 million (58%) in the prior year.
• Operating Expenses: Totaled $6.9 million, up from $6.3 million, primarily due to increased marketing and CDMO expenses.
• Net Loss: $2.6 million or $0.11 per share, compared to a net loss of $2.3 million or $0.13 per share in Q1 2025.
• Adjusted EBITDA Loss: $1.2 million, consistent with the previous year.
• Cash Position: Cash and cash equivalents stood at $20.2 million, significantly up from $3.4 million a year ago.

2. Strategic Updates and Business Highlights

• Business Model: BioHarvest operates two primary business segments: Direct-to-Consumer (D2C) and Contract Development and Manufacturing Organization (CDMO).
• Leadership Transition: A new two-lens management approach has been implemented to optimize performance and capital allocation.
• Product Development: The company is advancing multiple projects, including a significant fragrance project and a partnership with Saffron Tech for saffron-derived compounds.
• Market Position: BioHarvest’s Botanical Synthesis platform has been validated through its flagship product, VINIA, and is positioned to expand into the fragrance and nutraceutical markets.

3. Forward Guidance and Outlook

• D2C Revenue Guidance: Expected to range from $38 million to $42 million for 2026, with an adjusted EBITDA profit of $0.5 million to $2 million.
• CDMO Revenue Guidance: Anticipated to be between $12 million and $14 million for 2026, including intercompany VINIA production.
• Adjusted EBITDA Loss: Expected to be between $4 million and $5 million for the year.
• New Product Launches: Continued focus on expanding the VINIA product line, including a new chewable product and seasonal marketing strategies.

4. Bad News, Challenges, or Points of Concern

• Marketing Strategy Impact: A deliberate reduction in marketing spend in early Q1 led to a decline in revenue compared to Q4 2025, although improvements are expected in subsequent quarters.
• Net Losses: The company continues to incur net losses, raising concerns about profitability in the near term.
• Operational Capacity: Current capacity constraints may limit the ability to meet demand until the new manufacturing facility is operational in late 2027.

5. Notable Q&A Insights

• Market Potential: The saffron market is described as a multibillion-dollar opportunity, with BioHarvest aiming to leverage its partnership with Saffron Tech for dietary supplements.
• CDMO Pipeline: The company is actively pursuing additional contracts and expects to announce 3 to 4 new projects by the end of the year.
• Fragrance Development: The CDMO division has signed a $1.2 million Stage 2 contract for a fragrance project, which is seen as a significant growth opportunity.
• Consumer Acquisition Metrics: The company is focusing on improving the lifetime value to customer acquisition cost ratio to enhance profitability and growth potential.

Overall, while BioHarvest Sciences shows promising growth in revenue and strategic initiatives, challenges remain in achieving profitability and operational capacity to meet future demand.